Company research
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.
CIK 1187953Updated Sep 27, 2026
SecurityCELZ · NASDAQ · equity
Name history
JOLLEY MARKETING INC · through May 13, 2016
CELZ price & chart
Loading TradingView…
NASDAQ:CELZ on TradingView ↗About the company
We are a biotechnology company dedicated to the advancement of regenerative therapeutics in the fields of immunotherapy, endocrinology, urology, neurology and orthopedics. Our platforms, therapies and products include the following:
In the news
Creative Medical Technology Holdings Expands ADAPT Trial Under New FDA Clearance and Rapidly Advances Toward Phase 3 Planning for Olastrocel in Chronic Lower Back Pain ↗
Recent filings
Entry into a Material Definitive Agreement · Unregistered Sales of Equity Securities
Items 1.01, 3.02, 9.01
Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year · Submission of Matters to a Vote of Security Holders
Items 5.03, 5.07, 9.01
10-Q filing
424B3 filing
EFFECT filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 7,809,525Source | 6,669,143Source | 10,715,190Source | 19,186,326Source |
| Current assets: | ||||
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | — | — | — | 0Source |
| Inventory, NetUSD | 0Source | 2,194Source | 6,594Source | 10,194Source |
| Assets, CurrentUSD | 7,399,014Source | 6,135,303Source | 10,270,898Source | 18,747,450Source |
| Prepaid Expense and Other Assets, CurrentUSD | 138,804Source | 192,707Source | 277,246Source | 338,120Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 284,880Source | 327,644Source | 371,394Source | 3,321,652Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | — | — |
| Common Stock, Value, IssuedUSD | 3,144Source | 1,749Source | 1,431Source | 14,077Source |
| Additional Paid in CapitalUSD | 78,108,422Source | 70,931,663Source | 69,711,749Source | 69,662,455Source |
| Retained Earnings (Accumulated Deficit)USD | -70,586,921Source | -64,591,913Source | -59,098,432Source | -53,811,858Source |
| Stockholders' Equity Attributable to ParentUSD | 7,514,645Source | 6,341,499Source | 10,343,796Source | 15,864,674Source |
| Liabilities and EquityUSD | 7,809,525Source | 6,669,143Source | 10,715,190Source | 19,186,326Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 284,880Source | 327,644Source | 371,394Source | 3,321,652Source |
| Accounts Payable, CurrentUSD | 270,686Source | 273,530Source | 317,280Source | 3,267,538Source |
| Stockholders' Equity Attributable to Noncontrolling InterestUSD | 10,000Source | — | — | — |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 0Source | 39,920Source | 39,920Source | 39,920Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -5,995,008Source | -5,493,481Source | — | -10,144,044Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation and amortization | — | — | — | — |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 3,485Source | 36,648Source | 36,648Source | 68,746Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | 0Source | -2,485Source |
| Increase (Decrease) in InventoriesUSD | -2,194Source | -4,400Source | -3,600Source | -672Source |
| Increase (Decrease) in Accounts PayableUSD | -2,842Source | -43,850Source | -2,950,258Source | 2,505,676Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -5,856,445Source | -5,301,292Source | -8,027,885Source | -7,796,966Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -50,500Source | 6,320,191Source | 3,445,185Source | -10,078,617Source |
| Cash flows from financing activities: | ||||
| Payments for Repurchase of Common StockUSD | 10,000Source | 174,964Source | 270,952Source | — |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 7,174,669Source | 1,454,636Source | -270,952Source | 15,472,232Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 1,267,724Source | — | — | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 7,208,126Source | 5,940,402Source | 3,466,867Source | 8,320,519Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 0Source | 0Source | 0Source | 0Source |
| Income Taxes Paid, NetUSD | 0Source | 0Source | 0Source | 0Source |
| Additional Financial Items | ||||
| AmortizationUSD | — | 0Source | 0Source | 0Source |
| Share-based Payment Arrangement, ExpenseUSD | — | — | — | 0Source |
| Amortization of Intangible AssetsUSD | 123,327Source | 110,452Source | 94,584Source | 92,084Source |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | — | 0Source |
| Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | -5,995,008Source | -5,493,481Source | -5,286,574Source | -10,144,044Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | 0Source | — | — | — |
| Nonoperating Income (Expense)USD | 147,806Source | 250,380Source | 333,558Source | 100,328Source |
| Operating ExpensesUSD | 6,146,620Source | 5,750,461Source | 5,625,532Source | 10,304,481Source |
| Payments to Acquire InvestmentsUSD | — | 0Source | 22,854,815Source | — |
| Proceeds from Contributions from ParentUSD | 10,000Source | — | — | — |
| Proceeds from Issuance of Common StockUSD | 7,174,669Source | 1,629,500Source | 0Source | 15,471,775Source |
| Unrealized Gain (Loss) on InvestmentsUSD | — | 0Source | 34,087Source | — |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 6,000Source | 11,000Source | 9,000Source | 88,600Source |
| Cost of Goods and Services Sold | — | — | — | — |
| Selling, General and Administrative ExpenseUSD | 3,763,497Source | 3,239,232Source | 3,560,309Source | 3,943,543Source |
| Operating Income (Loss)USD | -6,142,814Source | -5,743,861Source | -5,620,132Source | -10,244,372Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -5,995,008Source | -5,493,481Source | -5,286,574Source | -10,144,044Source |
| Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | 0Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | -5,995,008Source | -5,493,481Source | -5,286,574Source | -10,144,044Source |
| Earnings Per Share, BasicUSD per share | — | — | — | -0.93Source |
| Earnings Per Share, DilutedUSD per share | -2.52Source | -3.71Source | — | -0.93Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | — | 10,932,035Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 2,382,797Source | 1,480,420Source | — | 10,932,035Source |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | 123,327Source | 110,452Source | 94,584Source | 92,084Source |
| Depreciation, Depletion and Amortization, NonproductionUSD | — | 56,000Source | 56,000Source | — |
| Gross ProfitUSD | 3,806Source | 6,600Source | 5,400Source | 60,109Source |
| Interest and Other IncomeUSD | 147,806Source | 250,380Source | 333,558Source | — |
| Interest ExpenseUSD | — | — | — | 0Source |
| Interest Income, OtherUSD | — | — | 34,000Source | — |
| Nonoperating Income (Expense)USD | 147,806Source | 250,380Source | 333,558Source | 100,328Source |
| Operating ExpensesUSD | 6,146,620Source | 5,750,461Source | 5,625,532Source | 10,304,481Source |
| Other IncomeUSD | — | — | — | 100,328Source |
| Research and Development ExpenseUSD | 2,259,796Source | 2,400,777Source | 1,970,639Source | 6,268,854Source |
Offerings
Registration 333-297026
Filing attachments
celz_ex41.htm · 8-K · 2026-07-02
EX-4.1 2 celz_ex41.htm FORM OF INDUCEMENT WARRANT celz_ex41.htm EXHIBIT 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECU…
Read attachment ↗celz_ex41.htm · 8-K · 2025-10-31
EX-4.1 2 celz_ex41.htm FORM OF INDUCEMENT WARRANT celz_ex41.htm EXHIBIT 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECU…
Read attachment ↗celz_ex41.htm · 8-K · 2025-03-07
EX-4.1 2 celz_ex41.htm FORM OF INDUCEMENT WARRANT celz_ex41.htm EXHIBIT 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECU…
Read attachment ↗